TY - JOUR
T1 - Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
AU - Vilsbøll, Tina
AU - Brock, Birgitte
AU - Perrild, Hans Jørgen Duckert
AU - Levin, K
AU - Lervang, Hans-Henrik
AU - Kølendorf, Klaus Erik
AU - Krarup, T
AU - Schmitz, Ole
AU - Zdravkovic, M
AU - Le Thi Thanh, Xuan
AU - Madsbad, S
PY - 2008/2/1
Y1 - 2008/2/1
N2 - To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks. First- and second-phase insulin release were measured by means of the insulin-modified frequently sampled intravenous glucose tolerance test. Arginine-stimulated insulin secretion was measured during a hyperglycaemic clamp (20 mmol/l). Glucose effectiveness and insulin sensitivity were estimated by means of the insulin-modified frequently sampled intravenous glucose tolerance test.
AB - To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks. First- and second-phase insulin release were measured by means of the insulin-modified frequently sampled intravenous glucose tolerance test. Arginine-stimulated insulin secretion was measured during a hyperglycaemic clamp (20 mmol/l). Glucose effectiveness and insulin sensitivity were estimated by means of the insulin-modified frequently sampled intravenous glucose tolerance test.
U2 - 10.1111/j.1464-5491.2007.02333.x
DO - 10.1111/j.1464-5491.2007.02333.x
M3 - Journal article
C2 - 18201212
SN - 0742-3071
VL - 25
SP - 152
EP - 156
JO - Diabetic Medicine
JF - Diabetic Medicine
IS - 2
ER -